Yan Luo

ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models

Cherrie K. Donawho, Yan Luo, Yanping Luo et al. · Clinical Cancer Research · 2007 · 773 citations · Full text

Medicine, Oncology, Pharmacology +15

ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV

Péter Ferenci, David Bernstein, Jacob Lalezari et al. · New England Journal of Medicine · 2014 · 695 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study

Fiona Blackhall, Kevin Jao, Laurent Greillier et al. · Journal of Thoracic Oncology · 2021 · 258 citations · Full text

Medicine, Oncology, Pharmacology +16

Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage–SCLC: Results From the Phase 3 MERU Study

Melissa L. Johnson, Zanete Zvirbule, Åslaug Helland et al. · Journal of Thoracic Oncology · 2021 · 156 citations · Full text

Medicine, Oncology, Pharmacotherapy +8

Synthesis and SAR of novel tricyclic quinoxalinone inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1)

Julie M. Miyashiro, Keith W. Woods, Chang H. Park et al. · Bioorganic & Medicinal Chemistry Letters · 2009 · 107 citations · Full text

Life Sciences, Medicinal Chemistry, Pharmacology +10